Tuberculosis News and Research

Latest Tuberculosis News and Research

First modeling system developed for testing age-specific human immune responses to vaccines

A team of scientists at Boston Children's Hospital has developed the first modeling system for testing age-specific human immune responses to vaccines -- outside the body. The practical, cost-effective new platform, using all human components, is expected to accelerate and de-risk the development, assessment and selection of vaccines.

20 Nov 2018

2PG Company receives grant to develop sensitive, low-cost molecular diagnostic tests for tuberculosis

Two Pore Guys, Inc. today announced that the company has received a $2.8 million grant from the Bill & Melinda Gates Foundation to develop sensitive, low-cost molecular diagnostic tests for tuberculosis using its solid-state nanopore technology.

19 Nov 2018

New strategy to hinder emergence of antimicrobial-resistant pathogens

With many disease-causing bacteria ratcheting up their shields against current drugs, new tactics are vital to protect people from treatment-resistant infections.

17 Nov 2018

ECDC study estimates burden of infections caused by antibiotic-resistant bacteria

An ECDC study estimates the burden of five types of infections caused by antibiotic-resistant bacteria of public health concern in the European Union and in the European Economic Area.

6 Nov 2018

Slime in showerheads could harbour dangerous lung bacteria finds study

A study has shown that the showerheads contain slime that can be home to potentially dangerous bacteria which lead to severe lung disease. Mycobacterial bacteria are responsible for lung diseases explain experts.

4 Nov 2018

Lymph nodes serve as reservoirs of prolonged bacterial persistence during Mtb infection

Lymph nodes can contain large numbers of tuberculosis-causing bacteria and serve as long-term reservoirs of bacterial persistence, according to a study published November 1 in the open-access journal PLOS Pathogens by JoAnne Flynn of the University of Pittsburgh School of Medicine, and colleagues.

2 Nov 2018

Antibiotic found in dirt can destroy mutant mycobacteria responsible for TB, study suggests

For decades, doctors have been using antibiotics to fight tuberculosis. And consistently, the microbe responsible for the disease, Mycobacterium tuberculosis, has been fighting back. When confronted with current drugs, such as the antibiotic rifamycin, the bacterium often mutates in ways that make it resistant to the treatment.

1 Nov 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Video monitoring of TB therapy works well in urban and rural areas

Researchers from University of California San Diego School of Medicine, with statewide collaborators, report that patients who recorded videos of themselves taking tuberculosis medications better adhered to treatment than patients who were observed in-person.

16 Oct 2018

Global health innovation system fails to deliver affordable treatments to patients, says report

NHS patients are being let down by a global health innovation system which fails to deliver the treatments they need at prices that government can afford, according to a new report led by Professor Mariana Mazzucato, Director of the UCL Institute for Innovation and Public Purpose, in collaboration with STOPAIDS, Global Justice Now and Just Treatment.

15 Oct 2018

Healthcare systems fail to deliver at affordable prices finds report

According to a new report from Professor Mariana Mazzucato, Director of the UCL Institute for Innovation and Public Purpose (IIPP), in collaboration with STOPAIDS, Global Justice Now and Just Treatment, the NHS patients are not getting treatments at affordable process and this is a failure on part of the global health innovation system.

15 Oct 2018

Scripps Research scientists discover role of immune system double agent

Scientists at Scripps Research have discovered the role of an immune system double agent. This molecule, called USP18, can help curtail immune responses, but it can also open the door to bacterial infections, such as harmful listeria and staph infections.

5 Oct 2018

UConn chemists develop new antibiotic that can find and kill tuberculosis bacteria

Tuberculosis is a sneaky disease. The bacteria hide from antibiotics inside the very immune cells that are supposed to kill them, making treatment long and difficult. But in the November issue of ACS Infectious Diseases, UConn chemists report a new antibiotic that can find and kill tuberculosis bacteria where they hide.

4 Oct 2018

New ReFRAME drug repurposing collection offers hope for treating major diseases

Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?

4 Oct 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

NIAID releases strategic plan to expand knowledge of TB by using modern tools

Tuberculosis (TB) is the leading infectious cause of death worldwide, killing roughly 1.6 million people in 2017. In the past 200 years, TB claimed the lives of more than one billion people--more deaths than from malaria, influenza, smallpox, HIV/AIDS, cholera and plague combined.

27 Sep 2018

Diabetes patients with poor blood sugar control face highest risk of serious infections

A new study has shown that diabetes patients with the poorest control of their blood sugars face the highest risks of hospitalization and death due to infections.

26 Sep 2018

New TB vaccine effective in half of the population in phase II trials

GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.

26 Sep 2018

‘Trouble Brewing’ report highlights steps that governments can take to reduce alcohol-related harms

Alcohol is a leading contributor to death and disability worldwide, but governments haven’t responded to the issue with the attention, resources and action this urgent issue requires, says “Trouble Brewing,” a new report from global health and development organizations, Vital Strategies, the NCD Alliance, IOGT International and the Global Alcohol Policy Alliance.

25 Sep 2018

Tuberculosis News and Research

Latest Tuberculosis News and Research

First modeling system developed for testing age-specific human immune responses to vaccines

2PG Company receives grant to develop sensitive, low-cost molecular diagnostic tests for tuberculosis

New strategy to hinder emergence of antimicrobial-resistant pathogens

ECDC study estimates burden of infections caused by antibiotic-resistant bacteria

Slime in showerheads could harbour dangerous lung bacteria finds study

Lymph nodes serve as reservoirs of prolonged bacterial persistence during Mtb infection

Antibiotic found in dirt can destroy mutant mycobacteria responsible for TB, study suggests

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Video monitoring of TB therapy works well in urban and rural areas

Global health innovation system fails to deliver affordable treatments to patients, says report

Healthcare systems fail to deliver at affordable prices finds report

Scripps Research scientists discover role of immune system double agent

UConn chemists develop new antibiotic that can find and kill tuberculosis bacteria

New ReFRAME drug repurposing collection offers hope for treating major diseases

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

NIAID releases strategic plan to expand knowledge of TB by using modern tools

Diabetes patients with poor blood sugar control face highest risk of serious infections

New TB vaccine effective in half of the population in phase II trials

‘Trouble Brewing’ report highlights steps that governments can take to reduce alcohol-related harms

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Tuberculosis News and Research

Latest Tuberculosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in